Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 10,535 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 2 Interventional Results available

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

NCT01589302
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions
ibrutinib, Correlative laboratory samples, quality of life assessment
Drug · Other
Lead sponsor
Kami Maddocks, MD
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 3 Interventional Results available

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895
View directory record Official record
Conditions
Urinary Bladder Cancer, Muscle-invasive
Interventions
Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
39
States / cities
Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

NCT04221477
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Fontana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Trauma Center-Based Intervention for Adolescent Traumatic Injury Survivors

NCT05086757
View directory record Official record
Conditions
Traumatic Injury, Technology, Posttraumatic Stress Disorder, Adolescents
Interventions
TRRP, Enhanced Usual Care
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting No phase listed Observational

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

NCT06332131
View directory record Official record
Conditions
Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 1 Interventional

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

NCT01970722
View directory record Official record
Conditions
FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
4
States / cities
Corona, California • Duarte, California • Upland, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting No phase listed Observational

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

NCT04447651
View directory record Official record
Conditions
Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation, U2AF1 Gene Mutation, SRSF2 Gene Mutation
Interventions
Recommendation for treatment with immunotherapy
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Air Pollution, Asthma and Circadian Clocks

NCT03406351
View directory record Official record
Conditions
Asthma, Healthy
Interventions
Observational
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers

NCT03865472
View directory record Official record
Conditions
Cigarette Smoker, Current Every Day Smoker, Current Smoker
Interventions
Questionnaire Administration, Repetitive Transcranial Magnetic Stimulation, Sham Intervention
Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Not applicable Interventional

Improving Exercise Capacity With a Tailored Physical Activity Intervention

NCT05595577
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Heart; Functional Disturbance, Hodgkin Lymphoma, Quality of Life, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Exercise with Trainerize application, Cardiopulmonary exercise testing, MRI scan, Quality of Life Questionnaires, Cognitive and Brain Function Questionnaires, Blood draws
Other · Diagnostic Test · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

NCT04713475
View directory record Official record
Conditions
GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
Interventions
PBGM01
Biological
Lead sponsor
Gemma Biotherapeutics
Industry
Eligibility
1 Month to 24 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Oakland, California • Minneapolis, Minnesota • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 2 Interventional

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

NCT05690386
View directory record Official record
Conditions
Turner Syndrome
Interventions
Lonapegsomatropin, Somatropin
Biological · Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
1 Year to 10 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 2 Interventional

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

NCT06580054
View directory record Official record
Conditions
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Computed Tomography, Digital Photography, Magnetic Resonance Imaging, Pembrolizumab
Procedure · Other · Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 2 Interventional Results available

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

NCT02764541
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Tamoxifen, Palbociclib, Endocrine Therapy
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
11
States / cities
Stamford, Connecticut • Brewer, Maine • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Not applicable Interventional

Improving Access to Chiropractic Care in Community Health Centers

NCT06104605
View directory record Official record
Conditions
Lower Back Pain
Interventions
Institutional interventions, PCPs interventions, Patient interventions
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 3 Interventional Results available

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Enfortumab vedotin, Pembrolizumab, Cisplatin, Carboplatin, Gemcitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Tucson, Arizona • Burbank, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

NCT05207670
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
39
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 1 Interventional

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

NCT07223983
View directory record Official record
Conditions
Alcohol Use Disorder, Weight Loss, Bariatric Surgery Patients
Interventions
Semaglutide 1.0 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Not applicable Interventional

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

NCT06051942
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Localized Prostate Cancer
Interventions
Robotic Waterjet Treatment
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
Up to 80 Years · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
La Mesa, California • Glenview, Illinois • Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 2 Interventional

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

NCT01410942
View directory record Official record
Conditions
Prostate Cancer
Interventions
Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT)
Other · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Not applicable Interventional

Leveraging mHealth to Enable and Adapt CHW Strategies to Improve TB/HIV Patient Outcomes in SA

NCT04298905
View directory record Official record
Conditions
Adherence, Patient, TB, HIV/AIDS, Care Coordination
Interventions
CHW mHealth patient intervention for trigger escalation
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)

NCT06322888
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female
Interventions
Exercise Training Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 1 Interventional

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

NCT05176470
View directory record Official record
Conditions
Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Stage IV Melanoma
Interventions
Cyclophosphamide, Fludarabine, Lifileucel, Pembrolizumab, Therapeutic Conventional Surgery
Drug · Biological · Procedure
Lead sponsor
Richard Wu
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 15, 2026, 5:00 AM EST
Active, not recruiting Phase 1 Interventional

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

NCT07262268
View directory record Official record
Conditions
Familial Erythromelalgia
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 15, 2026, 5:00 AM EST